Anthelmintic activity of silver-extract nanoparticles synthesized from the combination of silver nanoparticles and M. charantia fruit extract.

BACKGROUND: Present study has been conducted to know the anthelmintic activity of polyaniline coated silver nanoparticles (AgNPs) synthesized from Momordica charantia fruit extract. METHODS: By reduction of AgNO3 in presence of NaBH4, silver nanoparticles were prepared. After mixing silver nanoparticles and extracts, coating was given on nanoparticles using polyaniline. Prepared nanoparticles were characterized by Visual, UV, FTIR spectroscopy, SEM techniques, and TEM analysis. RESULTS: The FTIR results implied that AgNPs were successfully synthesized and capped with bio-compounds present in the extract. The result showed that death times of worm were 35.12 ± 0.5 and 59.3 ± 0.3 minutes for M. charantia extract and Ag-nanoparticles individually. But when these two combined together, paralysis and death time fall drastically which were only 6.16 ± 0.6 and 9.1 ± 0.4 minutes respectively. Albendazole tablet was used as standard, which made worms death in 3.66 ± 0.1 minutes. CONCLUSION: Ag-Extract NPs showed strong anthelmintic activity against worm. This study has paved the way for further research to design new anthelmintic drug from the combination of M. charantia and AgNPs.

Biological efficacy of zinc oxide nanoparticles against diabetes: a preliminary study conducted in mice.

The antidiabetic, hypoglycemic and oral glucose tolerance test (OGTT) activities of zinc oxide nanoparticles (ZnONPs) were assessed in mice. ZnONPs were prepared by reacting Zn(NO3)2.6H2O and NaOH solution at 70°C with continuous stirring and then characterized by transmission electron microscopy (TEM) and scanning electron microscopy (SEM) techniques. Diabetes was induced by the intraperitoneal injection of streptozotocin (STZ) in mice, and then the blood glucose levels were determined by the glucose oxidase method. The experimental results revealed that ZnONPs suggestively (p<0.001) declined the blood glucose levels (39.79%), while these reductions were 38.78% for the cotreatment of ZnONPs and insulin, and 48.60% for insulin, respectively. In the hypoglycemic study, ZnONPs (8 and 14 mg/kg b.w) reduced approximately 25.13 and 29.15% of blood glucose levels, respectively. A similar reduction was found in the OGTT test, which is also a dose- and time-dependent manner. Overall, ZnONPs possess a potential antidiabetic activity, which could be validated by further mechanistic studies.